US3596161097 - Common Stock
FULCRUM THERAPEUTICS INC
NASDAQ:FULC (4/26/2024, 3:30:00 PM)
After market: 7.14 0 (0%)7.14
+0.01 (+0.14%)
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 89 full-time employees. The company went IPO on 2019-07-18. The firm is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). The firm has developed a product engine to identify and validate cellular drug targets that can modulate gene expression to treat known root causes of genetically defined diseases. The Company’s product engine integrates patient-derived tissue and disease-relevant cell models that it interrogates using its pharmacologically diverse and annotated small-molecule compound library and customized CRISPR and RNAi libraries.
FULCRUM THERAPEUTICS INC
26 Landsdowne Street
Cambridge MASSACHUSETTS 02139
P: 16176518851
CEO: Robert J. Gould
Employees: 89
Website: https://www.fulcrumtx.com/
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...
―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a...
Here you can normally see the latest stock twits on FULC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: